Thiago J Borges, PhD
@tjborges.bsky.social
Transplant biologist and immunologist | Instructor
@MGHSurgery @mgh_transplant @HarvardMed. Posts are my own
@MGHSurgery @mgh_transplant @HarvardMed. Posts are my own
Thanks for highlighting our work!
May 19, 2025 at 2:29 PM
Thanks for highlighting our work!
💡 Takeaway: Innate immune checkpoints like Siglec-E/7/9 are emerging as crucial regulators of transplant rejection. 4/4
📄 Newsroom @mgbresearch.bsky.social: www.massgeneralbrigham.org/en/about/new...
📄 Newsroom @mgbresearch.bsky.social: www.massgeneralbrigham.org/en/about/new...
Discovery from MGB Researchers Yields Insights on Preventing Organ Transplant Rejection | Mass General Brigham
The study identifies receptors that slow inflammation, signaling a promising target for new therapies.
www.massgeneralbrigham.org
May 7, 2025 at 8:46 PM
💡 Takeaway: Innate immune checkpoints like Siglec-E/7/9 are emerging as crucial regulators of transplant rejection. 4/4
📄 Newsroom @mgbresearch.bsky.social: www.massgeneralbrigham.org/en/about/new...
📄 Newsroom @mgbresearch.bsky.social: www.massgeneralbrigham.org/en/about/new...
✅ Blocking NF-κB or TNF-α in Siglec–E–deficient models restores graft survival.
✅ In humans, higher expression of SIGLEC7/9 (homologs of Siglec-E) is linked to better allograft outcomes —highlighting their potential as biomarkers or therapeutic targets. 3/4
✅ In humans, higher expression of SIGLEC7/9 (homologs of Siglec-E) is linked to better allograft outcomes —highlighting their potential as biomarkers or therapeutic targets. 3/4
May 7, 2025 at 8:46 PM
✅ Blocking NF-κB or TNF-α in Siglec–E–deficient models restores graft survival.
✅ In humans, higher expression of SIGLEC7/9 (homologs of Siglec-E) is linked to better allograft outcomes —highlighting their potential as biomarkers or therapeutic targets. 3/4
✅ In humans, higher expression of SIGLEC7/9 (homologs of Siglec-E) is linked to better allograft outcomes —highlighting their potential as biomarkers or therapeutic targets. 3/4
✅ Siglec-E suppresses dendritic cell activation, limiting NF-κB signaling and TNF-α production.
✅ Loss of Siglec-E accelerates rejection in murine heart, kidney, and skin transplants through heightened T cell–mediated immunity. 2/4
✅ Loss of Siglec-E accelerates rejection in murine heart, kidney, and skin transplants through heightened T cell–mediated immunity. 2/4
May 7, 2025 at 8:46 PM
✅ Siglec-E suppresses dendritic cell activation, limiting NF-κB signaling and TNF-α production.
✅ Loss of Siglec-E accelerates rejection in murine heart, kidney, and skin transplants through heightened T cell–mediated immunity. 2/4
✅ Loss of Siglec-E accelerates rejection in murine heart, kidney, and skin transplants through heightened T cell–mediated immunity. 2/4